Pentti Põder - Concepedia

Author

Pentti Põder

Orion Corporation (Finland)ORCID

Also Known As

Mohamed Abdel Ghany Koriem, Mohamed Wafaie Aboleineen, P Põder, P. Poder, Pentti Poder, Pentti Põder

Publications

6.3K

Citations

H-Index

Concepts

All Affiliations

Orion Corporation (Finland)Helsinki University Hospital Hôpital Lariboisière London School of Hygiene & Tropical Medicine Charité - Universitätsmedizin Berlin

About

Pentti Põder is an author at Orion Corporation (Finland) specializing in cardiovascular disease, medicine, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	161
2	Pharmacology	4	4	120
3	Critical Care Medicine	1	1	12
4	Cardiovascular Pharmacodynamics	1	1	15
5	Hypertension	1	1	36

Pentti Põder

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure Alexandre Mebazaa, Markku S. Nieminen, Milton Packer, JAMA	2007	969
Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure Maria Nikolaou, John Parissis, Marie‐France Seronde, European Heart Journal	2012	309
A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus Dimitrios Farmakis, Piergiuseppe Agostoni, Loant Baholli, International Journal of Cardiology	2019	63
Oral Levosimendan in Patients with Severe Chronic Heart Failure—The PERSIST Study Markku S. Nieminen, John G.F. Cleland, Jaan Eha, European Journal of Heart Failure	2008	60
RUSSLAN STUDY INVESTIGATORS. SAFETY AND EFFICACY OF A NOVEL CALCIUM SENSITIZER, LEVOSIMENDAN, IN PATIENTS WITH LEFT VENTRICULAR FAILURE DUE TO AN ACUTE MYOCARDIAL INFARCTION. A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY (RUSSLAN) V.S. Moiseyev, Pentti Põder, Nikolajs Andrejevs, Heart FailureCardiovascular DiseaseA RandomizedMedicineMyocardial Infarction	2002	50
Pharmacodynamics and Pharmacokinetics of Oral Levosimendan and Its Metabolites in Patients With Severe Congestive Heart Failure: A Dosing Interval Study Pentti Põder, Jaan Eha, Stig Sundberg, The Journal of Clinical Pharmacology HypertensionHeart FailureHeart RatePharmacological StudyCardiovascular Disease	2004	36
Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry Giuseppe Ambrosio, M.G. Crespo Leiro, Lars H. Lund, European Journal of Internal Medicine Hf LtUrologyHeart FailureSerum Uric AcidCardiovascular Disease	2021	29
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. a randomized, placebo-controlled, double-blind study (RUSSLAN) V.S. Moiseyev, Pentti Põder, Nikolajs Andrejevs ACC Current Journal Review Heart FailureCardiogenic ShockCardiovascular DiseaseMedicineCardiovascular Pharmacology	2003	19
Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure. Pentti Põder, Jaan Eha, S. Sundberg, PubMed	2003	19
Pharmacodynamic Interactions of Levosimendan and Felodipine in Patients with Coronary Heart Disease Pentti Põder, Jaan Eha, Saila Antila, Cardiovascular Drugs and Therapy Pharmacological StudyCardiovascular DiseasePharmacologyCardiovascular PharmacologyPharmacodynamic Interactions	2003	15

Page 1